Acutaas Chemicals Peer Comparison
NSE: ACUTAAS | BSE: 543349
₹3,710.00
₹-83.30
(-2.20%)
As on 28-Oct-2026IST
Market cap
₹30,346 Cr
Revenue (TTM)
₹1,593 Cr
P/E Ratio
69.1
P/B Ratio
16.3
Div. Yield
0.1 %
Edit
| Acutaas Chemicals | Piramal Pharma | Onesource Specialty Pharma | Syngene Intl | Beta Drugs | |
|---|---|---|---|---|---|
Market cap (₹ Cr) |
30,346 | 30,994 | 18,044 | 16,619 | 2,198 |
Revenue (₹ Cr) |
1,593 | 9,779 | 1,684 | 3,522 | 444 |
Net Profit (₹ Cr) |
438.64 | -270.51 | -1.62 | 186.10 | 53.34 |
Net Margin (%) |
27.16 | -2.71 | -0.10 | 5.15 | 11.78 |
RoE (%) |
25.02 | -2.55 | 0.22 | 4.93 | 15.21 |
Price to Earnings |
69.10 | -- | -- | 89.30 | 42.34 |
Price-To-Book |
16.34 | 3.81 | 3.05 | 3.42 | 5.02 |
Income Statement (₹ Cr)
| Acutaas Chemicals | Piramal Pharma | Onesource Specialty Pharma | Syngene Intl | Beta Drugs | |
|---|---|---|---|---|---|
|
Operating Revenue
|
1,592.52 | 9,778.62 | 1,683.82 | 3,522.30 | 444.27 |
|
Total Income
|
1,615.23 | 9,993.26 | 1,695.30 | 3,613.20 | 452.81 |
|
Total Expenditure
|
969.32 | 8,578.44 | 1,287.94 | 2,771.50 | 351.96 |
|
EBITDA
|
623.20 | 1,200.18 | 395.88 | 750.80 | 92.31 |
|
Depreciation
|
41.96 | 887.82 | 288.26 | 449.10 | 18.14 |
|
EBIT
|
581.24 | 312.36 | 107.62 | 301.70 | 74.17 |
|
Interest
|
4.21 | 347.94 | 126.12 | 43.60 | 12.58 |
|
Other Income
|
22.71 | 214.64 | 11.47 | 90.90 | 8.54 |
|
Exceptional Items
|
0.00 | -216.88 | -13.12 | -96.80 | 0.00 |
|
Profit before Tax
|
599.74 | -37.82 | -20.14 | 252.20 | 70.12 |
|
Provision for Tax
|
161.10 | 232.69 | -18.52 | 66.10 | 16.79 |
|
Profit after Tax
|
438.64 | -270.51 | -1.62 | 186.10 | 53.34 |
Liabilities (₹ Cr)
| Acutaas Chemicals | Piramal Pharma | Onesource Specialty Pharma | Syngene Intl | Beta Drugs | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
1,857.45 | 8,142.24 | 5,920.89 | 4,858.80 | 437.70 |
|
Minority Interest
|
0.51 | 0.55 | 0.00 | 0.00 | -1.42 |
|
Non-Current Liabilities
|
47.15 | 5,213.99 | 1,001.58 | 616.80 | 37.20 |
|
Current Liabilities
|
253.37 | 5,158.51 | 1,663.61 | 1,182.90 | 144.38 |
|
Total Liabilities
|
1,983.96 | 17,723.32 | 8,222.05 | 7,054.70 | 503.72 |
Assets (₹ Cr)
| Acutaas Chemicals | Piramal Pharma | Onesource Specialty Pharma | Syngene Intl | Beta Drugs | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
1,132.12 | 10,687.30 | 6,364.60 | 3,950.40 | 232.30 |
|
Current Assets
|
1,012.00 | 7,253.65 | 1,697.49 | 1,948.10 | 379.62 |
|
Total Assets
|
1,983.96 | 17,723.32 | 8,222.05 | 7,054.70 | 503.72 |
|
Total Debt*
|
26.49 | 5,495.48 | 1,276.30 | 9.40 | 147.81 |
|
Net Current Assets
|
758.64 | 2,095.14 | 33.87 | 765.20 | 235.24 |
|
Contingent Liabilities
|
17.25 | 95.72 | 1,287.25 | 536.50 | -- |
Cashflow (₹ Cr)
| Acutaas Chemicals | Piramal Pharma | Onesource Specialty Pharma | Syngene Intl | Beta Drugs | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
292.17 | 1,652.60 | 8.52 | 915.20 | 37.29 |
|
Cash Flow from Investing Activities
|
-265.94 | -826.03 | -494.98 | -860.40 | -51.39 |
|
Cash from Financing Activities
|
4.10 | -38.98 | 359.44 | -215.00 | -8.07 |
|
Net Cash Inflow / Outflow
|
30.33 | 787.59 | -127.02 | -160.20 | -22.18 |
Ratios
Profitability Ratios
| Acutaas Chemicals | Piramal Pharma | Onesource Specialty Pharma | Syngene Intl | Beta Drugs | |
|---|---|---|---|---|---|
|
ROCE (%)
|
32.42 | 1.24 | 0.44 | 9.48 | 19.16 |
|
ROE (%)
|
25.02 | -2.55 | 0.22 | 4.93 | 15.21 |
|
ROA (%)
|
22.40 | -1.56 | -0.02 | 2.82 | 16.25 |
|
EBIT Margin (%)
|
36.50 | 3.19 | 6.39 | 8.57 | 16.69 |
|
Net Margin (%)
|
27.16 | -2.71 | -0.10 | 5.15 | 11.78 |
|
Cash Profit Margin (%)
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Growth Ratios
| Acutaas Chemicals | Piramal Pharma | Onesource Specialty Pharma | Syngene Intl | Beta Drugs | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
45.18 | 9.43 | 10.66 | -5.99 | 15.20 |
|
EBIT Growth (%)
|
115.51 | -3.72 | -55.98 | -48.77 | 19.55 |
|
Net Profit Growth (%)
|
95.80 | -199.34 | -103.99 | -60.25 | 27.30 |
|
EPS Growth (%)
|
63.29 | -410.28 | -91.16 | -49.04 | 6.38 |
|
Book Value Growth (%)
|
26.03 | 0.33 | -0.75 | 2.11 | 24.19 |
Valuation Ratios
| Acutaas Chemicals | Piramal Pharma | Onesource Specialty Pharma | Syngene Intl | Beta Drugs | |
|---|---|---|---|---|---|
|
Price / Earnings
|
69.10 | -149.04 | 1,407.04 | 69.48 | 40.93 |
|
Price / Book Value
|
16.34 | 3.81 | 3.05 | 3.42 | 5.02 |
|
Dividend Yield (%)
|
0.07 | 0.00 | 0.00 | 0.30 | 0.00 |
|
EV/EBITDA
|
48.37 | 29.27 | 48.54 | 20.43 | 24.06 |
|
Market Cap (₹ Cr)
|
20,944.75 | 18,108.89 | 16,876.12 | 15,723.10 | 1,205.58 |
Solvency Ratios
| Acutaas Chemicals | Piramal Pharma | Onesource Specialty Pharma | Syngene Intl | Beta Drugs | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.02 | 0.55 | 0.10 | 0.00 | 0.06 |
|
Short term debt to equity ratio
|
0.00 | 0.09 | 0.10 | 0.00 | 0.03 |
|
Current Ratio
|
3.99 | 1.41 | 1.02 | 1.65 | 2.63 |
|
Quick Ratio
|
2.89 | 0.77 | 0.75 | 1.51 | 2.06 |
|
Interest Coverage
|
143.52 | 0.89 | 0.84 | 6.78 | 6.57 |
Operating Efficiency Ratios
| Acutaas Chemicals | Piramal Pharma | Onesource Specialty Pharma | Syngene Intl | Beta Drugs | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
22.50 | 23.05 | 61.34 | 10.94 | 37.69 |
|
Asset Turnover
|
0.81 | 0.56 | 0.20 | 0.53 | 1.35 |
|
Receivable days
|
88.98 | 78.20 | 140.79 | 50.33 | 105.14 |
|
Inventory Days
|
56.04 | 93.30 | 75.94 | 14.43 | 63.66 |
|
Payable days
|
99.95 | 226.14 | 225.76 | 17,487.50 | 161.92 |
|
Cash Conversion Cycle
|
45.07 | -54.64 | -9.03 | -17,422.74 | 6.88 |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
loading...
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
